Drug – bio-affecting and body treating compositions – Immunoglobulin – antiserum – antibody – or antibody fragment,... – Binds hormone or other secreted growth regulatory factor,...
Reexamination Certificate
2000-07-26
2002-08-13
Kemmerer, Elizabeth (Department: 1647)
Drug, bio-affecting and body treating compositions
Immunoglobulin, antiserum, antibody, or antibody fragment,...
Binds hormone or other secreted growth regulatory factor,...
C424S130100, C512S002000, C512S008000, C530S300000, C530S350000, C530S387100, C530S399000
Reexamination Certificate
active
06432406
ABSTRACT:
FIELD OF THE INVENTION
This invention relates to a method of enhancing wound healing and to a method of enhancing organ transplantation comprising the administration of scatter factor to promote angiogenesis.
BACKGROUND OF THE INVENTION
Scatter factor has previously been described as a cytokine which is secreted by fibroblasts (see Stroker et al.,
J. Cell Sci.,
Vol. 77, pp. 209-223 (1985) and Stoker et al.,
Nature
(London), Vol. 327, pp. 238-242 (1987)) and by vascular smooth muscle cells (see Rosen et al.,
In Vitro Cell Dev. Biol.,
Vol. 25, pp. 163-173 (1989)). Scatter factor has been shown to disperse cohesive epithelial colonies and stimulate cell motility. In addition, scatter factor has been shown to be identical to hepatocyte growth factor (HGF) (see Weidner et al.,
Proc. Nat'l. Acad. Sci. USA
, Vol. 88, pp. 7001-7005 (1991) and Bhargava et al.,
Cell Growth Differ.,
Vol. 3, pp. 11-20 (1992)), which is an independently characterized serum mitogen (see Miyazawa et al.,
Biochem. Biophys. Res. Commun
., Vol. 169, pp. 967-973 (1989) and Nakumura et al.,
Nature
(
London
), Vol. 342, pp. 440-443 (1989)). Scatter factor induces kidney epithelial cells in a collagen matrix to form branching networks of tubules, suggesting that it can also act as a morphogen (see Montesano et al.,
Cell
, Vol. 67, pp. 901-908 (1991)).
Scatter factor (HGF) is a basic heparin-binding glycoprotein consisting of a heavy (58 kDa) and a light (31 kDa) subunit. It has 38% amino acid sequence identity with the proenzyme plasminogen (see Nakumura et al.,
Nature
(
London
), Vol. 342, pp. 440-443 (1989)) and is thus related to the blood coagulation family of proteases. Its receptor in epithelium has been identified as the c-met protooncogene product, a transmembrane tyrosine kinase (see Bottaro et al.,
Science
, Vol. 251, pp. 803-804 (1991) and Naldini et al.,
Oncogene
, Vol. 6, pp. 501-504 (1991)).
Scatter factor has been found to stimulate endothelial chemotactic and random migration in Boyden chambers (see Rosen et al.,
Proc. Soc. Exp. Biol. Med.,
Vol. 195, pp. 34-43 (1990)); migration from carrier beads to flat surfaces (see Rosen et al.,
Proc. Soc. Exp. Biol. Med.,
Vol. 195, pp. 34-43 (1990)); formation of capillary-like tubes (see Rosen et al.,
Cell Motility Factors
, (Birkhauser, Basel) pp. 76-88 (1991)) and DNA synthesis (see Rubin et al.,
Proc. Nat'l Acad. Sci
l USA, Vol. 88, pp. 415-419 (1991)). In addition, preliminary studies have suggested that scatter factor induces endothelial secretion of plasminogen activators (see Rosen et al.,
Cell Motility Factors
, (Birkhauser, Basel) pp. 76-88 (1991)).
The term “angiogenesis”, as used herein, refers to the formation of blood vessels. Specifically, angiogenesis is a multistep process in which endothelial cells focally degrade and invade through their own basement membrane, migrate through interstitial stroma toward an angiogenic stimulus, proliferate proximal to the migrating tip, organize into blood vessels, and reattach to newly synthesized basement membrane (see Folkman et al.,
Adv. Cancer Res.,
Vol. 43, pp. 175-203 (1985)). These processes are controlled by soluble factors and by the extracellular matrix (see Ingber et al.,
Cell
, Vol. 58, pp. 803-805 (1985)).
Because proteases, such as plasminogen activators (the endothelial secretion of which is induced by scatter factor) are required during the early stages of angiogenesis, and since endothelial cell migration, proliferation and capillary tube formation occur during angiogenesis, the inventors hypothesized that scatter factor might enhance angiogenic activity in vivo. In addition, it is desirable to enhance angiogenic activity so that would healing and organ transplantation can be enhanced.
It is therefore an object of this invention to provide a method of enhancing angiogenic activity.
It is a further object of this invention to provide a method of enhancing wound healing.
It is a still further object of this invention to provide a method of enhancing organ transplantation.
SUMMARY OF THE INVENTION
This invention is directed to a method of promoting angiogenesis by administration of scatter factor. The promotion of angiogenesis can be used for promoting would healing and treating various conditions where the promotion of angiogenesis is desirable, including, but not limited to, ischemia.
REFERENCES:
patent: 5837676 (1998-11-01), Goldberg et al.
patent: 5919759 (1999-07-01), Goldberg et al.
patent: 5965523 (1999-10-01), Goldberg et al.
patent: 5997868 (1999-12-01), Goldberg et al.
patent: 6011009 (2000-01-01), Goldberg et al.
patent: 6013624 (2000-01-01), Goldberg et al.
Presenti et al. British Journal of Cancer 66: 367-372, 1992.*
Bussolino et al. Journal of Cell Biology 119(3): 629-641, 1992.*
Adams et al. Journal of Cell Science 98: 385-394, 1991.*
Hori et al. Cancer Research 51: 6180-6184, 1991.*
Grant et al. Proc Natl Acad Sci USA 90: 1937-1941, 1993.*
Rosen et al. Proc Soc Exp Biol Med 195 : 34-42, 1990.*
Naldini et al. Oncogene 6 : 501-504, 1991.*
Rubin et al. Proc Natl Acad Sci USA 88: 415-419, 1991.*
Bhargava et al. Cell Growth and Differentiation 3 : 11-20, 1992.*
Weidner et al. Journal of Cell Biology 121(1) : 145-154, 1993.*
Jiang et al. British Journal of Surgery 80(11) : 1368-1373, 1993.*
Rubin et al. Biochimica et Biophysica Acta-Review on Cancer 1155(3): 357-371, 1993.*
Montesano et al. Cell 67 : 901-908, 1991.*
Stoker et al. Nature 327 : 228-242, 1987.*
Weidner et al. Proc Natl Acad Sci USA 88 : 7001-7005, 1991.*
Rosen et al. inCell Motility Factors, (Birkhauser, Basel) p. 76-88, 1991.
Goldberg Itzhak D.
Rosen Eliot M.
Amster Rothstein & Ebenstein
Bunner Bridget E.
Kemmerer Elizabeth
North Shore - Long Island Jewish Research Institute
LandOfFree
Method for reducing angiogenesis by administration of a... does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Method for reducing angiogenesis by administration of a..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Method for reducing angiogenesis by administration of a... will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-2893060